Royalty Report: Drugs, Cancer, Biotechnology – Collection: 29334


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Biotechnology
  • Antibody

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29334

License Grant
Parties hereto shall work together to complete the research and development of anti-tumor drug AL6802 (a chemical compound that covered by the pending U.S. patent and the future PCT patent application mentioned above) in China (and other countries and regions outside China), and finally have AL6802 Pharmaceutical registration and invention patent granted in China mainland and carry out relevant commercial development in China and other countries and regions outside China. The period for the royalties shall be the patent protection period of AL6802 in China.  Al-6802 belongs to a series of small molecules developed that have very potent activity at in vitro human cancer cell proliferation assay and in vivo human cancer cell A431 xenograft model.
Field of Use
This compound is targeting epidermal growth factor receptor (EGFR) for cancer treatment.

IPSCIO Record ID: 284140

License Grant
Licensor granted Licensee worldwide exclusive development and commercialization rights to capmatinib and certain back-up compounds in all indications.
License Property
Capmatinib is a potent and highly selective MET inhibitor. The investigational compound has demonstrated inhibitory activity in cell-based biochemical and functional assays that measure MET signaling and MET dependent cell proliferation, survival and migration.
c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF). These inhibitors may have therapeutic application in the treatment of various types of cancers.
Field of Use
Capmatinib is being evaluated in patients with hepatocellular carcinoma, non-small cell lung cancer and other solid tumors, and may have potential utility as a combination agent.

IPSCIO Record ID: 383584

License Grant
Licensor grants a worldwide exclusive right and license under Know-how, with the right to sublicense others, to make, have made, use, sell, offer for sale and import Licensed Products.

Licensor grants an exclusive license under Patent Rights, with respect to Licensors fifty percent ownership interest in such Patent Rights, with the right to sublicense others, to make, have made, use, sell, offer for sale and import Licensed Products in all jurisdictions outside the United States.

License Property
Licensed Products shall mean Erbitux®, and matuzumab  as well as all derivatives, analogs, fragments, improvements, conjugates and bioequivalents of any of the foregoing.

Erbitux® shall mean cetuximab, and marketed as Erbitux®.

ERBITUX (cetuximab) is an epidermal growth factor receptor (EGFR) inhibitor. EGFR is a receptor found on both normal and tumor cells that is important for cell growth.

The patent is titled Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same.

Field of Use
Erbitux ( cetuximab) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.